Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03237845 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy in Adult Subjects With Acute Migraines
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,499
- Enrollment target
NCT03237845 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 1,499 participants.
The verdict
NCT03237845, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,499 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the efficacy of BHV-3000 (rimegepant) versus placebo in subjects with Acute Migraines
Interventions
- DRUG Placebo
- DRUG Rimegepant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,499 participants |
| Start Date | 2017-07-27 |
| Est. Completion | 2018-01-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03237845
The ClinicalTrials.gov registry entry for NCT03237845 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,499 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03237845 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03237845 about?
NCT03237845 is a clinical study titled "Safety and Efficacy in Adult Subjects With Acute Migraines". The purpose of this study is to compare the efficacy of BHV-3000 (rimegepant) versus placebo in subjects with Acute Migraines
What is the current status of trial NCT03237845?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,499 participants. The study started on 2017-07-27. Estimated completion is 2018-01-31.
What interventions are being tested in trial NCT03237845?
The interventions under investigation include: Placebo (DRUG), Rimegepant (DRUG).
Who is sponsoring clinical trial NCT03237845?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.